Curanex Pharmaceuticals Inc Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CURX research report →
Companywww.curanexpharma.com
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc.
- CEO
- Jun Liu
- IPO
- 2025
- HQ
- Jericho, NY, US
Price Chart
Valuation
- Market Cap
- $9.42M
- P/E
- -1.30
- P/S
- 0.00
- P/B
- 1.17
- EV/EBITDA
- -0.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -85.41%
- ROIC
- -86.83%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,225,106 · -1068.75%
- EPS
- $-0.17 · -1207.69%
- Op Income
- $-4,239,076
- FCF YoY
- -1787.14%
Performance & Tape
- 52W High
- $9.18
- 52W Low
- $0.26
- 50D MA
- $0.42
- 200D MA
- $1.01
- Beta
- -3.22
- Avg Volume
- 4.37M
Get TickerSpark's AI analysis on CURX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 25 | Xie Liqin | other | 0 |
| Aug 25, 25 | Hsu Helen Hong | other | 0 |
| Aug 25, 25 | Zhong Huijuan | other | 0 |
| Aug 25, 25 | Yan Yong | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Hao Xiaohui | other | 0 |
Our CURX Coverage
We haven't published any research on CURX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CURX Report →